Associations - HER2 inhibitor

HER-2 amplification + RAS wild-type + BRAF wild-type	Colon Cancer	HER-2 amplification + RAS wild-type + BRAF wild-type	Colon Cancer	trastuzumab + tucatinib Sensitive: A2 - Guideline NCCN - 1 week (New A2) trastuzumab + tucatinib Sensitive : A2 NCCN - 1wk	trastuzumab + tucatinib Sensitive: A2 - Guideline NCCN - 1 week trastuzumab + tucatinib Sensitive : A2 NCCN - 1 week - (New A2)
HER-2 amplification + RAS wild-type + BRAF wild-type	Rectal Cancer	HER-2 amplification + RAS wild-type + BRAF wild-type	Rectal Cancer	trastuzumab + tucatinib Sensitive: A2 - Guideline NCCN - 1 week (New A2) trastuzumab + tucatinib Sensitive : A2 NCCN - 1wk	trastuzumab + tucatinib Sensitive: A2 - Guideline NCCN - 1 week trastuzumab + tucatinib Sensitive : A2 NCCN - 1 week - (New A2)
RET fusion + TP53 mutation	HER2 Positive Breast Cancer	RET fusion + TP53 mutation	HER2 Positive Breast Cancer	pyrotinib Resistant: C4 – Case Studies Anticancer Drugs - 1 week (New C4) pyrotinib Resistant : C4 Anticancer Drugs - 1wk	pyrotinib Resistant: C4 – Case Studies Anticancer Drugs - 1 week pyrotinib Resistant : C4 Anticancer Drugs - 1 week - (New C4)
HER-2 positive	HER2 Positive Breast Cancer	HER-2 positive	HER2 Positive Breast Cancer	dasatinib + lapatinib Sensitive: D – Preclinical PLoS One - 1 week (New D) dasatinib + lapatinib Sensitive : D PLoS One - 1wk	dasatinib + lapatinib Sensitive: D – Preclinical PLoS One - 1 week dasatinib + lapatinib Sensitive : D PLoS One - 1 week - (New D)
RAS wild-type + HER-2 positive	Colorectal Cancer	RAS wild-type + HER-2 positive	Colorectal Cancer	trastuzumab + tucatinib Sensitive: A1 - Approval FDA - 2 weeks (New A1) trastuzumab + tucatinib Sensitive : A1 FDA - 2wk	trastuzumab + tucatinib Sensitive: A1 - Approval FDA - 2 weeks trastuzumab + tucatinib Sensitive : A1 FDA - 2 weeks - (New A1)
HER-2 expression	Gastroesophageal Cancer	HER-2 expression	Gastroesophageal Cancer	ZW25 Sensitive: C3 – Early Trials ASCO-GI 2023 - 2 weeks (New C3) ZW25 Sensitive : C3 ASCO-GI 2023 - 2wk	ZW25 Sensitive: C3 – Early Trials ASCO-GI 2023 - 2 weeks ZW25 Sensitive : C3 ASCO-GI 2023 - 2 weeks - (New C3)
BRAF wild-type + HER-2 positive	Colorectal Cancer	BRAF wild-type + HER-2 positive	Colorectal Cancer	trastuzumab + pertuzumab Sensitive: C3 – Early Trials ASCO-GI 2023 - 2 weeks (New C3) trastuzumab + pertuzumab Sensitive : C3 ASCO-GI 2023 - 2wk	trastuzumab + pertuzumab Sensitive: C3 – Early Trials ASCO-GI 2023 - 2 weeks trastuzumab + pertuzumab Sensitive : C3 ASCO-GI 2023 - 2 weeks - (New C3)
RAS wild-type + HER-2 positive	Colorectal Cancer	RAS wild-type + HER-2 positive	Colorectal Cancer	trastuzumab + pertuzumab Sensitive: C3 – Early Trials ASCO-GI 2023 - 2 weeks (New C3) trastuzumab + pertuzumab Sensitive : C3 ASCO-GI 2023 - 2wk	trastuzumab + pertuzumab Sensitive: C3 – Early Trials ASCO-GI 2023 - 2 weeks trastuzumab + pertuzumab Sensitive : C3 ASCO-GI 2023 - 2 weeks - (New C3)
HER-2 positive	Gastroesophageal Junction Adenocarcinoma	HER-2 positive	Gastroesophageal Junction Adenocarcinoma	camrelizumab + pyrotinib Sensitive: C3 – Early Trials ASCO-GI 2023 - 2 weeks (New C3) camrelizumab + pyrotinib Sensitive : C3 ASCO-GI 2023 - 2wk	camrelizumab + pyrotinib Sensitive: C3 – Early Trials ASCO-GI 2023 - 2 weeks camrelizumab + pyrotinib Sensitive : C3 ASCO-GI 2023 - 2 weeks - (New C3)
HER-2 positive	Gastric Cancer	HER-2 positive	Gastric Cancer	camrelizumab + pyrotinib Sensitive: C3 – Early Trials ASCO-GI 2023 - 2 weeks (New C3) camrelizumab + pyrotinib Sensitive : C3 ASCO-GI 2023 - 2wk	camrelizumab + pyrotinib Sensitive: C3 – Early Trials ASCO-GI 2023 - 2 weeks camrelizumab + pyrotinib Sensitive : C3 ASCO-GI 2023 - 2 weeks - (New C3)
KRAS mutation	Biliary Tract Cancer	KRAS mutation	Biliary Tract Cancer	trastuzumab + pertuzumab Resistant: C3 – Early Trials ASCO-GI 2023 - 2 weeks (New C3) trastuzumab + pertuzumab Resistant : C3 ASCO-GI 2023 - 2wk	trastuzumab + pertuzumab Resistant: C3 – Early Trials ASCO-GI 2023 - 2 weeks trastuzumab + pertuzumab Resistant : C3 ASCO-GI 2023 - 2 weeks - (New C3)
ERBB3 mutation + HER-2 amplification	Biliary Tract Cancer	ERBB3 mutation + HER-2 amplification	Biliary Tract Cancer	trastuzumab + pertuzumab Sensitive: C3 – Early Trials ASCO-GI 2023 - 2 weeks (New C3) trastuzumab + pertuzumab Sensitive : C3 ASCO-GI 2023 - 2wk	trastuzumab + pertuzumab Sensitive: C3 – Early Trials ASCO-GI 2023 - 2 weeks trastuzumab + pertuzumab Sensitive : C3 ASCO-GI 2023 - 2 weeks - (New C3)
HER-2 mutation	Biliary Tract Cancer	HER-2 mutation	Biliary Tract Cancer	trastuzumab + pertuzumab Sensitive: C3 – Early Trials ASCO-GI 2023 - 2 weeks (New C3) trastuzumab + pertuzumab Sensitive : C3 ASCO-GI 2023 - 2wk	trastuzumab + pertuzumab Sensitive: C3 – Early Trials ASCO-GI 2023 - 2 weeks trastuzumab + pertuzumab Sensitive : C3 ASCO-GI 2023 - 2 weeks - (New C3)
HER-2 amplification	Biliary Tract Cancer	HER-2 amplification	Biliary Tract Cancer	trastuzumab + pertuzumab Sensitive: C3 – Early Trials ASCO-GI 2023 - 2 weeks (New C3) trastuzumab + pertuzumab Sensitive : C3 ASCO-GI 2023 - 2wk	trastuzumab + pertuzumab Sensitive: C3 – Early Trials ASCO-GI 2023 - 2 weeks trastuzumab + pertuzumab Sensitive : C3 ASCO-GI 2023 - 2 weeks - (New C3)
EGFR exon 20 insertion	Non Small Cell Lung Cancer	EGFR exon 20 insertion	Non Small Cell Lung Cancer	mobocertinib Sensitive: A1 - Approval Takeda Press Release - 3 weeks (New A1) mobocertinib Sensitive : A1 Takeda Press Release - 3wk	mobocertinib Sensitive: A1 - Approval Takeda Press Release - 3 weeks mobocertinib Sensitive : A1 Takeda Press Release - 3 weeks - (New A1)
EGFR exon 19 deletion	Non Small Cell Lung Cancer	EGFR exon 19 deletion	Non Small Cell Lung Cancer	afatinib Sensitive: A1 - Approval afatinib Sensitive : A1	afatinib Sensitive: A1 - Approval afatinib Sensitive : A1
EGFR L858R	Non Small Cell Lung Cancer	EGFR L858R	Non Small Cell Lung Cancer	afatinib Sensitive: A1 - Approval afatinib Sensitive : A1	afatinib Sensitive: A1 - Approval afatinib Sensitive : A1
HER-2 positive	HER2 Positive Breast Cancer	HER-2 positive	HER2 Positive Breast Cancer	trastuzumab + tucatinib Sensitive: A1 - Approval trastuzumab + tucatinib Sensitive : A1	trastuzumab + tucatinib Sensitive: A1 - Approval trastuzumab + tucatinib Sensitive : A1
HER-2 positive	HER2 Positive Breast Cancer	HER-2 positive	HER2 Positive Breast Cancer	trastuzumab + pertuzumab Sensitive: A1 - Approval trastuzumab + pertuzumab Sensitive : A1	trastuzumab + pertuzumab Sensitive: A1 - Approval trastuzumab + pertuzumab Sensitive : A1
HER-2 positive	HER2 Positive Breast Cancer	HER-2 positive	HER2 Positive Breast Cancer	margetuximab Sensitive: A1 - Approval margetuximab Sensitive : A1	margetuximab Sensitive: A1 - Approval margetuximab Sensitive : A1
HER-2 positive	Gastroesophageal Junction Adenocarcinoma	HER-2 positive	Gastroesophageal Junction Adenocarcinoma	trastuzumab Sensitive: A1 - Approval trastuzumab Sensitive : A1	trastuzumab Sensitive: A1 - Approval trastuzumab Sensitive : A1
EGFR mutation	Non Small Cell Lung Cancer	EGFR mutation	Non Small Cell Lung Cancer	afatinib Sensitive: A1 - Approval afatinib Sensitive : A1	afatinib Sensitive: A1 - Approval afatinib Sensitive : A1
HER-2 positive	HER2 Positive Breast Cancer	HER-2 positive	HER2 Positive Breast Cancer	trastuzumab Sensitive: A1 - Approval trastuzumab Sensitive : A1	trastuzumab Sensitive: A1 - Approval trastuzumab Sensitive : A1
HER-2 positive	Gastric Cancer	HER-2 positive	Gastric Cancer	pembrolizumab + trastuzumab Sensitive: A1 - Approval pembrolizumab + trastuzumab Sensitive : A1	pembrolizumab + trastuzumab Sensitive: A1 - Approval pembrolizumab + trastuzumab Sensitive : A1
HR positive	HER2 Positive Breast Cancer	HR positive	HER2 Positive Breast Cancer	neratinib Sensitive: A1 - Approval neratinib Sensitive : A1	neratinib Sensitive: A1 - Approval neratinib Sensitive : A1
HER-2 overexpression	Gastric Cancer	HER-2 overexpression	Gastric Cancer	trastuzumab Sensitive: A1 - Approval trastuzumab Sensitive : A1	trastuzumab Sensitive: A1 - Approval trastuzumab Sensitive : A1
HER-2 positive	HER2 Positive Breast Cancer	HER-2 positive	HER2 Positive Breast Cancer	pertuzumab/trastuzumab/hyaluronidase-zzxf Sensitive: A1 - Approval pertuzumab / trastuzumab / hyaluronidase-zzxf Sensitive : A1	pertuzumab/trastuzumab/hyaluronidase-zzxf Sensitive: A1 - Approval pertuzumab / trastuzumab / hyaluronidase-zzxf Sensitive : A1
HER-2 amplification	Hormone Receptor Positive Breast Cancer	HER-2 amplification	Hormone Receptor Positive Breast Cancer	trastuzumab-qyyp Sensitive: A1 - Approval trastuzumab-qyyp Sensitive : A1	trastuzumab-qyyp Sensitive: A1 - Approval trastuzumab-qyyp Sensitive : A1
HER-2 overexpression	Hormone Receptor Positive Breast Cancer	HER-2 overexpression	Hormone Receptor Positive Breast Cancer	trastuzumab-qyyp Sensitive: A1 - Approval trastuzumab-qyyp Sensitive : A1	trastuzumab-qyyp Sensitive: A1 - Approval trastuzumab-qyyp Sensitive : A1
HER-2 amplification	HER2 Positive Breast Cancer	HER-2 amplification	HER2 Positive Breast Cancer	trastuzumab-qyyp Sensitive: A1 - Approval trastuzumab-qyyp Sensitive : A1	trastuzumab-qyyp Sensitive: A1 - Approval trastuzumab-qyyp Sensitive : A1
HER-2 overexpression	HER2 Positive Breast Cancer	HER-2 overexpression	HER2 Positive Breast Cancer	trastuzumab-qyyp Sensitive: A1 - Approval trastuzumab-qyyp Sensitive : A1	trastuzumab-qyyp Sensitive: A1 - Approval trastuzumab-qyyp Sensitive : A1
HER-2 positive	Gastroesophageal Junction Adenocarcinoma	HER-2 positive	Gastroesophageal Junction Adenocarcinoma	trastuzumab-qyyp Sensitive: A1 - Approval trastuzumab-qyyp Sensitive : A1	trastuzumab-qyyp Sensitive: A1 - Approval trastuzumab-qyyp Sensitive : A1
HER-2 overexpression	Gastric Cancer	HER-2 overexpression	Gastric Cancer	trastuzumab-qyyp Sensitive: A1 - Approval trastuzumab-qyyp Sensitive : A1	trastuzumab-qyyp Sensitive: A1 - Approval trastuzumab-qyyp Sensitive : A1
HER-2 amplification	Hormone Receptor Positive Breast Cancer	HER-2 amplification	Hormone Receptor Positive Breast Cancer	trastuzumab-dttb Sensitive: A1 - Approval trastuzumab-dttb Sensitive : A1	trastuzumab-dttb Sensitive: A1 - Approval trastuzumab-dttb Sensitive : A1
HER-2 overexpression	Hormone Receptor Positive Breast Cancer	HER-2 overexpression	Hormone Receptor Positive Breast Cancer	trastuzumab-dttb Sensitive: A1 - Approval trastuzumab-dttb Sensitive : A1	trastuzumab-dttb Sensitive: A1 - Approval trastuzumab-dttb Sensitive : A1
HER-2 amplification	HER2 Positive Breast Cancer	HER-2 amplification	HER2 Positive Breast Cancer	trastuzumab-dttb Sensitive: A1 - Approval trastuzumab-dttb Sensitive : A1	trastuzumab-dttb Sensitive: A1 - Approval trastuzumab-dttb Sensitive : A1
HER-2 overexpression	HER2 Positive Breast Cancer	HER-2 overexpression	HER2 Positive Breast Cancer	trastuzumab-dttb Sensitive: A1 - Approval trastuzumab-dttb Sensitive : A1	trastuzumab-dttb Sensitive: A1 - Approval trastuzumab-dttb Sensitive : A1
HER-2 positive	Gastroesophageal Junction Adenocarcinoma	HER-2 positive	Gastroesophageal Junction Adenocarcinoma	trastuzumab-dttb Sensitive: A1 - Approval trastuzumab-dttb Sensitive : A1	trastuzumab-dttb Sensitive: A1 - Approval trastuzumab-dttb Sensitive : A1
HER-2 overexpression	Gastric Cancer	HER-2 overexpression	Gastric Cancer	trastuzumab-dttb Sensitive: A1 - Approval trastuzumab-dttb Sensitive : A1	trastuzumab-dttb Sensitive: A1 - Approval trastuzumab-dttb Sensitive : A1
HER-2 amplification	Hormone Receptor Positive Breast Cancer	HER-2 amplification	Hormone Receptor Positive Breast Cancer	trastuzumab-dkst Sensitive: A1 - Approval trastuzumab-dkst Sensitive : A1	trastuzumab-dkst Sensitive: A1 - Approval trastuzumab-dkst Sensitive : A1
HER-2 overexpression	Hormone Receptor Positive Breast Cancer	HER-2 overexpression	Hormone Receptor Positive Breast Cancer	trastuzumab-dkst Sensitive: A1 - Approval trastuzumab-dkst Sensitive : A1	trastuzumab-dkst Sensitive: A1 - Approval trastuzumab-dkst Sensitive : A1
HER-2 amplification	HER2 Positive Breast Cancer	HER-2 amplification	HER2 Positive Breast Cancer	trastuzumab-dkst Sensitive: A1 - Approval trastuzumab-dkst Sensitive : A1	trastuzumab-dkst Sensitive: A1 - Approval trastuzumab-dkst Sensitive : A1
HER-2 overexpression	HER2 Positive Breast Cancer	HER-2 overexpression	HER2 Positive Breast Cancer	trastuzumab-dkst Sensitive: A1 - Approval trastuzumab-dkst Sensitive : A1	trastuzumab-dkst Sensitive: A1 - Approval trastuzumab-dkst Sensitive : A1
HER-2 positive	Gastroesophageal Junction Adenocarcinoma	HER-2 positive	Gastroesophageal Junction Adenocarcinoma	trastuzumab-dkst Sensitive: A1 - Approval trastuzumab-dkst Sensitive : A1	trastuzumab-dkst Sensitive: A1 - Approval trastuzumab-dkst Sensitive : A1
HER-2 overexpression	Gastric Cancer	HER-2 overexpression	Gastric Cancer	trastuzumab-dkst Sensitive: A1 - Approval trastuzumab-dkst Sensitive : A1	trastuzumab-dkst Sensitive: A1 - Approval trastuzumab-dkst Sensitive : A1
HER-2 amplification	Hormone Receptor Positive Breast Cancer	HER-2 amplification	Hormone Receptor Positive Breast Cancer	trastuzumab-anns Sensitive: A1 - Approval trastuzumab-anns Sensitive : A1	trastuzumab-anns Sensitive: A1 - Approval trastuzumab-anns Sensitive : A1
HER-2 overexpression	Hormone Receptor Positive Breast Cancer	HER-2 overexpression	Hormone Receptor Positive Breast Cancer	trastuzumab-anns Sensitive: A1 - Approval trastuzumab-anns Sensitive : A1	trastuzumab-anns Sensitive: A1 - Approval trastuzumab-anns Sensitive : A1

HER2 inhibitor

HER2 inhibitor

Associations(1029)

Associations
(1029)